Toward a Standard Practice to Quantify von Willebrand Factor Degradation During Left Ventricular Assist Device Support

被引:10
|
作者
Hennessy-Strahs, Samson [1 ]
Bermudez, Christian A. [1 ]
Acker, Michael A. [1 ]
Bartoli, Carlo R. [1 ]
机构
[1] Hosp Univ Penn, Div Cardiovasc Surg, 3400 Spruce St, Philadelphia, PA 19104 USA
来源
ANNALS OF THORACIC SURGERY | 2021年 / 112卷 / 04期
关键词
LONG-TERM SUPPORT; FACTOR PROFILES; HIGH PREVALENCE; IMPLANTATION; CENTRIFUGAL; CONTRIBUTES;
D O I
10.1016/j.athoracsur.2020.09.039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Continuous-flow left ventricular assist devices (LVADs) cause degradation of von Willebrand factor (VWF) multimers and bleeding. Multiple techniques exist to characterize VWF deficiency. However, a standard methodology has not been established in LVAD patients. Toward this goal, we evaluated 4 methods to quantify VWF multimers. Methods. We collected paired blood samples from patients (n = 48) before and after 1 week of LVAD support. After 652 +/- 59 days of support, patients were classified as bleeders (>= 1 bleeding episode) or nonbleeders. VWF mul- timers were resolved with electrophoresis and immuno-blotting, the gold-standard to evaluate VWF multimers. We evaluated 4 quantification methods. Results. Each method demonstrated significant VWF degradation during LVAD support vs a paired, pre-LVAD sample (method 1, VWF length: 48 of 48 patients, -10% +/- 1%, P < .0001; method 2, VWF density: 40 of 48, -34% (interquartile range, -46% to -8%), P < .0001; method 3, pre-LVAD to LVAD ratio: 46 of 48, 17 +/- 5: 10 +/- 1, P < .0001; method 4, LVAD/pre-LVAD index: 46 of 48, 57% (inter-quartile range, 50% to 73%), P < .0001). Bleeding occurred in 27 of 48 patients. Method 1 demonstrated significantly fewer VWF multimers in bleeders compared with non-bleeders (-11% +/- 1% vs -8% +/- 1%; P = .01). Other methods did not demonstrate this potentially important clinical relationship. Conclusions. A standardized methodology is needed to quantify VWF multimer degradation with mechanical circulatory support devices. Novel method 1 successfully quantified the patient-specific change in VWF multimer length during LVAD support and demonstrated a difference in VWF multimers between bleeders and non-bleeders. Adoption of consensus methodology will assist to standardize patient-specific bleeding risk, inform anticoagulation and antiplatelet therapy, and evaluate LVAD hemocompatibility. (C) 2021 by The Society of Thoracic Surgeons
引用
收藏
页码:1257 / 1264
页数:8
相关论文
共 50 条
  • [1] Hemolysis and Von Willebrand Factor Levels During Continuous Flow Left Ventricular Assist Device Support
    Saeed, O.
    Rangasamy, S.
    Luke, A.
    Patel, S. R.
    Shin, J.
    Sims, D. B.
    Gil, M. Reyes
    Goldstein, D. J.
    Slepian, M. J.
    Billett, H. H.
    Jorde, U.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S247 - S247
  • [2] von Willebrand factor proteolysis by ADAMTS-13 in patients on left ventricular assist device support
    Nascimbene, Angelo
    Hilton, Tristan
    Konkle, Barbara A.
    Moake, Joel L.
    Frazier, O. H.
    Dong, Jing-fei
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : 477 - 479
  • [3] A new spin on acquired von Willebrand factor deficiency during continuous-flow left ventricular assist device support
    Toole, John M.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2015, 149 (01): : 289 - U436
  • [4] Preclinical Models for Translational Investigations of Left Ventricular Assist Device-Associated von Willebrand Factor Degradation
    Restle, David J.
    Zhang, David M.
    Hung, George
    Howard, Jessica L.
    Kallel, Faouzi
    Acker, Michael A.
    Atluri, Pavan
    Bartoli, Carlo R.
    ARTIFICIAL ORGANS, 2015, 39 (07) : 569 - 575
  • [5] Left Ventricular Assist Device Design Reduces von Willebrand Factor Degradation: A Comparative Study Between the HeartMate II and the EVAHEART Left Ventricular Assist System
    Bartoli, Carlo R.
    Kang, Jooeun
    Zhang, David
    Howard, Jessica
    Acker, Michael
    Atluri, Pavan
    Motomura, Tadashi
    ANNALS OF THORACIC SURGERY, 2017, 103 (04): : 1239 - 1245
  • [6] Clinical and In Vitro Evidence That Left Ventricular Assist Device-Induced von Willebrand Factor Degradation Alters Angiogenesis
    Bartoli, Carlo R.
    Zhang, David M.
    Hennessy-Strahs, Samson
    Kang, Jooeun
    Restle, David J.
    Bermudez, Christian
    Atluri, Pavan
    Acker, Michael A.
    CIRCULATION-HEART FAILURE, 2018, 11 (09) : e004638
  • [7] Reduced continuous-flow left ventricular assist device speed does not decrease von Willebrand factor degradation
    Kang, Jooeun
    Zhang, David M.
    Restle, David J.
    Kallel, Faouzi
    Acker, Michael A.
    Atluri, Pavan
    Bartoli, Carlo R.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2016, 151 (06): : 1747 - +
  • [8] Von Willebrand factor, a versatile player in gastrointestinal bleeding in left ventricular assist device recipients?
    Fischer, Quentin
    Huisse, Marie-Genevieve
    Voiriot, Guillaume
    Caron, Claudine
    Lepage, Laurent
    Dilly, Marie-Pierre
    Nataf, Patrick
    Ajzenberg, Nadine
    Kirsch, Matthias
    TRANSFUSION, 2015, 55 (01) : 51 - 54
  • [9] The "double whammy" of a continuous-flow left ventricular assist device on von Willebrand factor
    Hydren, Jay R.
    Richardson, Russell S.
    Wever-Pinzon, Omar
    Drakos, Stavros G.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2020, 159 (03): : 910 - 915
  • [10] Acquired von Willebrand syndrome associated with left ventricular assist device
    Nascimbene, Angelo
    Neelamegham, Sriram
    Frazier, O. H.
    Moake, Joel L.
    Dong, Jing-fei
    BLOOD, 2016, 127 (25) : 3133 - 3141